The association between PCSK9 and inflammation provides a compelling rationale for the therapeutic use of PCSK9 inhibitors in preventing atherosclerosis and its severe consequences, such as myocardial ischemia. This evidence concerns the gene PCSK9 and myocardial ischemia.